Dr. Stuart Titus, President and CEO of Medical Marijuana, Inc., reviews the history of medical marijuana and outlines the body of research that has been done on cannabis thus far.
Our resident expert on cannabinoids and the endocannabinoid system, Dr. Titus walks you through the complicated past of medical marijuana, including its removal from the U.S. pharmacopeia and the discovery of cannabinoids and the cannabinoid system in the 20th century.His presentation also includes work being done by two of Medical Marijuana, Inc.’s portfolio companies, Kannalife™ Sciences and AXIM® Biotechnologies. Using licenses on the government’s patent #6,630,507, Cannabinoids as Antioxidants and Neuroprotectants, Kannalife™ Sciences has developed a synthetic form of CBD that is 50 times more potent than natural CBD. With this synthetic cannabinoid, the company hopes to develop a novel treatment for both hepatic encephalopathy (HE) and chronic traumatic encephalopathy (CTE), a pair of degenerative brain disorders. AXIM® Biotechnologies is currently working with CBG, another cannabinoid found in hemp, in a line of oral care products and to develop a topical treatment for eczema and psoriasis.
Dr. Titus shares his expertise weekly in his column Dr. Titus’ Insights. If there is a topic you’d like to Dr. Titus to cover, submit it to him with this form for a chance to have him answer your questions in future columns.